For instance, All-trans-retinoic acid, employed for the therapy of acute promyelocytic leukemia, has been suggested as a specific Nrf2 inhibitor, which permits Nrf2 to form a complex with retinoid X receptor alpha (RARα), inhibiting stimulation of the Nrf2 pathway [117]. This evidence concerns the gene NFE2L2 and acute promyelocytic leukemia.